Univariable Fine and Gray model for rehospitalisation (event of interest) and death without rehospitalisation (competing event) due to AHF
| Rehospitalisation | Death without rehospitalisation | |||||
| SHR | 95% CI | P value | SHR | 95% CI | P value | |
| Gender | 0.360 | 0.170 | ||||
| Male | 1 | - | 1 | - | ||
| Female | 1.18 | 0.83 to 1.69 | 0.72 | 0.44 to 1.15 | ||
| Age group | 0.410 | 0.004 | ||||
| ≤79 years | 1 | - | 1 | - | ||
| ≥80 years | 0.87 | 0.62 to 1.22 | 2.16 | 1.28 to 3.62 | ||
| LVEF | 0.610 | 0.030 | ||||
| ≤40% | 1 | - | 1 | - | ||
| >40% | 1.1 | 0.76 to 1.59 | 0.6 | 0.37 to 0.96 | ||
| Hypertension | 0.020 | 0.200 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 2.37 | 1.15 to 4.89 | 0.65 | 0.33 to 1.26 | ||
| Diabetes | 0.040 | 0.280 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.43 | 1.02 to 2.02 | 0.77 | 0.48 to 1.24 | ||
| Active cancer | 0.800 | 0.010 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.1 | 0.55 to 2.21 | 2.33 | 1.19 to 4.55 | ||
| Chronic pulmonary disease | 0.650 | 0.880 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.09 | 0.76 to 1.57 | 0.96 | 0.57 to 1.62 | ||
| Stroke | 0.270 | 0.410 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 0.76 | 0.47 to 1.23 | 1.27 | 0.72 to 2.23 | ||
| PAD | 0.130 | 0.410 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.55 | 0.87 to 2.74 | 1.33 | 0.68 to 2.59 | ||
| Dementia | 0.220 | <0.001 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 0.76 | 0.49 to 1.17 | 2.58 | 1.59 to 4.20 | ||
| Need for caregiving | 0.400 | 0.030 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.19 | 0.79 to 1.77 | 1.78 | 1.06 to 3.00 | ||
| AF | 0.002 | 0.350 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.72 | 1.21 to 2.44 | 1.26 | 0.78 to 2.04 | ||
| Sleep apnoea/hypoventilation syndrome | 0.400 | 0.150 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.19 | 0.79 to 1.79 | 0.59 | 0.29 to 1.20 | ||
| ACEi | 0.600 | 0.020 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.1 | 0.78 to 1.55 | 0.55 | 0.34 to 0.89 | ||
| Beta-blocker | 0.030 | 0.030 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.49 | 1.05 to 2.10 | 0.59 | 0.37 to 0.96 | ||
| MRA | 0.160 | 0.870 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 1.36 | 0.89 to 2.10 | 1.05 | 0.56 to 1.96 | ||
| Oral anticoagulant | 0.660 | 0.660 | ||||
| No | 1 | - | 1 | - | ||
| Yes | 0.917 | 0.63 to 1.34 | 0.89 | 0.53 to 1.50 | ||
| PCr (discharge)* | 1.98 | 1.37 to 2.85 | <0.001 | 1.6 | 0.86 to 2.97 | 0.140 |
| PUr (discharge)* | 1.81 | 1.27 to 2.57 | 0.001 | 1.23 | 0.73 to 2.05 | 0.440 |
| PK+ (discharge) | 1.44 | 1.04 to 2.00 | 0.030 | 0.69 | 0.43 to 1.11 | 0.130 |
| PNa+ (discharge)* | 0.09 | 0.00 to 4.78 | 0.240 | 0.35 | 0.01 to 25.5 | 0.630 |
| SBP (admission) | 1 | 1.00 to 1.01 | 0.370 | 1 | 0.99 to 1.00 | 0.300 |
| PDW (admission) | 1.01 | 0.94 to 1.09 | 0.770 | 0.88 | 0.80 to 0.96 | 0.004 |
| RDW (admission)* | ||||||
| Q1 | 1 | - | 1 | - | ||
| Q2 | 0.94 | 0.57 to 1.55 | 0.820 | 1.2 | 0.55 to 2.60 | 0.650 |
| Q3 | 0.88 | 0.52 to 1.49 | 0.640 | 1.55 | 0.73 to 3.29 | 0.250 |
| Q4 | 1.78 | 1.14 to 2.77 | 0.010 | 2.75 | 1.38 to 5.52 | 0.004 |
| Platelet (admission)* | 0.98 | 0.62 to 1.57 | 0.950 | 1.17 | 0.57 to 2.39 | 0.670 |
| Htc (admission) | 0.98 | 0.95 to 1.00 | 0.070 | 0.94 | 0.91 to 0.98 | <0.001 |
| Hgb (admission) | 0.92 | 0.85 to 0.99 | 0.020 | 0.85 | 0.77 to 0.94 | 0.002 |
*Logarithm transformation.
ACEi, ACE inhibitor; AF, atrial fibrillation; AHF, acute heart failure; Hgb, haemoglobin; Htc, haematocrit; LVEF, left ventricle ejection fraction; MRA, mineralocorticoid receptor antagonist; PAD, peripheral arterial disease; PCr, plasma creatinine; PDW, platelet distribution width; PK+, plasma potassium; PNa+, plasma sodium; PUr, plasma urea; Q, quartile; RDW, red cell distribution width; SBP, systolic blood pressure; SHR, subdistribution HR.